Table 1.

Study design and baseline characteristics

Author	Year	Study design	Patient	Mean age	Male, N (%)	ECOG score				Extrahepatic metastases N (%)	Evidence level	Prechemotherapy N (%)	Postchemotherapy N (%)
0	1	2	3
Saxena et al26	2010	PC	25	57	13 (52.0)	15	7	3	0	12 (48.0)	Moderate	18 (72.0)	7 (28.0)
Mosconi et al25	2016	RC	23	65	14 (60.9)	18	5	0	0	2 (8.7)	Low	12 (52.2)	4 (17.4)
Rafi et al24	2013	PC	19	63.3	7 (36.8)	1	14	4	0	11 (57.9)	Moderate	19 (100.0)	N/A
Mouli et al23	2013	PC	46	68a	25 (54.3)	24	21	1	0	16 (34.8)	Moderate	16 (34.8)	N/A
Hoffmann et al22	2012	RC	33	65.2	18 (54.5)	17	7	9	0	8 (24.2)	Moderate	27 (78.8)	N/A
Jia et al21	2017	RC	24	61.8	8 (33.3)	16	8	0	0	3 (12.5)	Moderate	24 (100.0)	N/A
Soydal et al20	2016	RC	16	55.4	8 (50.0)	N/A	N/A	N/A	N/A	5 (31.3)	Moderate	9 (56.3)	N/A
Swinburne et al19	2017	RC	29	66	14 (48.3)	11	13	5	0	11 (37.9)	Moderate	15 (51.7）	N/A
Reimer et al18	2018	RC	21	69.5	12 (57.1)	0	3	16	2	3 (14.3)	Moderate	0 (0.0)	N/A
Orwat et al17	2017	RC	16	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Moderate	N/A	N/A
Paprottka et al16	2017	RC	35	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Moderate	N/A	N/A
Gangi et al13	2018	RC	85	73.4	41 (48.2)	35	22	28	0	36 (42.4)	Moderate	61 (71.8)	6(7.1)
Filippi et al11	2015	PC	17	59.4	6 (35.3)	N/A	N/A	N/A	N/A	4 (23.5)	Moderate	15 (88.2)	N/A
Beuzit et al12	2016	RC	45	64a	24 (53.3)	25	20		0	N/A	Moderate	41 (91.1)	N/A
Shaker et al14	2018	RC	17	69.3	7 (41.2)	N/A	N/A	N/A	N/A	7 (41.2)	Moderate	5 (29.4)	3 (17.6)
Camacho et al15	2014	PC	21	62.7a	13 (62.0)	9	8	3	0	N/A	Moderate	21 (100.0)	N/A

Note: ^aMedian age.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; RC, Retrospective cohort; PC, Prospective cohort; N/A, not available.